Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-Dosing Temozolomide in Melanoma
NCT00591370Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2005
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Objective Response Rate. Started Jan 2005; status: completed.
02
Drugs
temozolomide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00591370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00591370.